Skip to main
XAIR

XAIR Stock Forecast & Price Target

XAIR Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Beyond Air Inc has demonstrated significant growth in its financial performance, evidenced by a fiscal 3Q26 revenue of $2.2 million, marking a 105% increase compared to previous periods. The company's successful sale of its LungFit PH system to a VA Medical Center and the expansion of its international distribution to 40 countries further enhance its commercial prospects. Additionally, promising interim Phase 1 data for its UNO monotherapy highlights a favorable safety profile and potential therapeutic benefits, reinforcing the company's innovative position in the medical device and biopharmaceutical market.

Bears say

Beyond Air Inc faces challenges in positioning its Nitric Oxide Generator and Delivery System, as management shifts its focus from a niche ablation tool to a potential immunotherapy enhancer, which may complicate its market strategy and commercial acceptance. Additionally, the company's reliance on innovative combinations with existing therapies, like anti-PD-1 treatments, raises uncertainties regarding clinical effectiveness and competitive advantage in a crowded market. Financially, the lack of consistent revenue streams and potential delays in product adoption could hinder growth prospects and investor confidence.

XAIR has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beyond Air Inc (XAIR) Forecast

Analysts have given XAIR a Strong Buy based on their latest research and market trends.

According to 1 analysts, XAIR has a Strong Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beyond Air Inc (XAIR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.